✦ LIBER ✦

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

✍ Scribed by Salvatore Del Prete; Liliana Montella; Michele Caraglia; Luigi Maiorino; Gregorio Cennamo; Vincenzo Montesarchio; Guido Piai; Antonio Febbraro; Luciano Tarantino; Elena Capasso; Giovannella Palmieri; Rosario Guarrasi; Maddalena Bianco; Rosanna Mamone; Clementina Savastano; Agata Pisano; Bruno Vincenzi; Antonietta Sabia; Alberto D’Agostino; Vincenzo Faiola; Raffaele Addeo

Book ID: 105993361
Publisher: Springer
Year: 2009
Tongue: English
Weight: 378 KB
Volume: 66
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1226-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of bevacizumab and erloti

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

✍ Thomas Yau, Hilda Wong, Pierre Chan, T. J. Yao, R. Pang, T. T. Cheung, S. T. Fan 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 156 KB

Efficacy and safety of sorafenib–gemcita

Efficacy and safety of sorafenib–gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study

✍ Naqi, Naeem; Ahmad, Shaharyar; Murad, Sohail; Khattak, Javaid 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 136 KB

4 SORAFENIB PLUS CISPLATIN AND GEMCITABI

4 SORAFENIB PLUS CISPLATIN AND GEMCITABINE IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II STUDY BY THE GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE (PROT. GOIM 2705)

✍ F. Giuliani; R. Addeo; A. Febbraio; D. Rizzi; E. Macello; S. del Prete; S. Pisco 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

AOSOP3 Combination of bevacizumab and er

AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

High dose toremifene (240 mg daily) is e

High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer an ongoing phase II multicenter Finnish-Latvian cooperative study

✍ Tenho Hietanen; Dace Baltina; Risto Johansson; Soile Numminen; Tapani Hakala; Le 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 273 KB

P4-389: An oral antagonist of the recept

P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study

✍ Sabbagh, Marwan N.; Bell, Joanne; Agro, Albert; Aisen, Paul; Galasko, Douglas 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB